ClinicalTrials.gg
CompletedNCT02952092Updated Oct 30, 2024

A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia

A Phase 3 interventional study of roxadustat and Darbepoetin alfa in Hemodialysis Chronic Kidney Disease Patients With Anemia, sponsored by Astellas Pharma Inc. Completed at 57 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
303
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
12th of 43
303 · median 154
Started
2016
with 3 others
Phase 3
25 of 43
1 open now
Registered
22nd of 43
by date
Lead sponsor
7 of 43
Astellas Pharma Inc

Among the 43 studies testing roxadustat in Anemia, this one is the 12th largest by enrollment, is one of 4 that started in 2016, is one of 25 in phase 3, and was the 22nd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and efficacy of ASP1517 compared to darbepoetin alfa in hemodialysis chronic kidney disease patients with anemia.

03

Conditions studied

  • Hemodialysis Chronic Kidney Disease Patients With Anemia

Browse trials for

Keywords

  • ASP1517
  • Renal anemia
  • Hemodialysis
  • Roxadustat
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with renal anemia who have been receiving recombinant human erythropoietin (rHuEPO, two times weekly or three times weekly) or darbepoetin alfa (intravenous treatment) within the doses approved in Japan for more than 8 weeks before the screening assessment
  • Mean of the subject's two most recent values before dialysis after the longest dialysis interval during the Screening Period must be ≥10.0 g/dL and ≤12.0 g/dL
  • Either transferrin saturation (TSAT) ≥ 20% or serum ferritin ≥ 100 ng/mL during the screening period
  • Female subject must either:

Be of non-:

  • (defined as at least 1 year without any menses) prior to Screening, or
  • documented surgically sterile Or, if of childbearing potential,
  • Agree not to try to become pregnant during the study and for 28 days after the final study drug administration
  • And have a negative pregnancy test at Screening
  • And, if heterosexually active, agree to consistently use two forms of highly effective form of (at least one of which must be a barrier method) starting at Screening and throughout the study period and continued for 28 days after the final study drug administration.

    • Female subject must agree not to breastfeed starting at Screening and throughout the study period, and continued for 28 days after the final study drug administration.
    • Female subject must not donate ova starting at Screening and throughout the study period, and continued for 28 days after the final study drug administration.
    • Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective form of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 12 weeks after the final study drug administration
    • Male subject must not donate sperm starting at Screening and throughout the study period and, for 12 weeks after the final study drug administration

Exclusion criteria

Exclusion Criteria:

  • Concurrent retinal neovascular lesion untreated and macular edema untreated
  • Concurrent disease with inflammation that could impact erythropoiesis
  • History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastroparesis
  • Uncontrolled hypertension
  • Concurrent congestive heart failure ( Class III or higher)
  • History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the screening assessment
  • Positive for surface antigen (HBsAg) or anti- virus (HCV) antibody at the screening assessment, or positive for (HIV) in a past test
  • Concurrent other form of anemia than renal anemia
  • History of pure red cell aplasia
  • Having received treatment with protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the screening assessment
  • (AST), Alanine Aminotransferase (ALT), or total that is greater than the criteria, or previous or concurrent another serious liver disease at screening assessment
  • Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)
  • Having undergone blood transfusion and/or a surgical procedure considered to promote anemia (excluding shunt reconstruction surgery for access to the blood) and/or ophthalmological surgery within 4 weeks before the screening assessment
  • Having undergone a kidney transplantation
  • Having a previous history of treatment with ASP1517
  • History of serious drug allergy including anaphylactic shock
  • Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before acquisition
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
303 participants (actual)

Study arms

  • Experimental
    ASP1517 Group

    Subjects will take the study drug at two- or three-day intervals.

    Drug: roxadustat

  • Experimental
    Darbepoetin alfa Group

    Subjects will take the study drug once a week.

    Drug: Darbepoetin alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the average hemoglobin (Hb)

    Time frame: Baseline and Weeks 18 to 24

Secondary outcomes

  1. Average Hb from Week 18 to Week 24

    Time frame: Week 18 to 24

  2. Proportion of participants with the target Hb level from Week 18 to Week 24

    Time frame: Week 18 to 24

  3. Proportion of participants with the target Hb level at each week

    Time frame: Up to Week 24

  4. Change from week 0 in Hb levels to each week

    Time frame: Up to Week 24

  5. Proportion of measurement points with the target Hb level from Week 18 to Week 24

    Time frame: Week 18 to 24

  6. Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment

    Time frame: Up to Week 4

  7. Average hematocrit level

    Time frame: Up to Week 24

  8. Average reticulocyte level

    Time frame: Up to Week 24

  9. Average iron (Fe) level

    Time frame: Up to Week 24

  10. Average ferritin level

    Time frame: Up to Week 24

  11. Average transferrin level

    Time frame: Up to Week 24

  12. Average total iron binding capacity level

    Time frame: Up to Week 24

  13. Average soluble transferrin receptor level

    Time frame: Up to Week 24

  14. Average transferrin saturation level

    Time frame: Up to Week 24

  15. Average reticulocyte hemoglobin content level

    Time frame: Up to Week 24

  16. Quality of life assessed by SF-36

    SF-36: Medical Outcomes Study 36-Item Short-Form Health Survey

    Time frame: Up to Week 24

  17. Quality of life assessed by EQ-5D-5L

    EQ-5D-5L: EuroQol 5 Dimension 5-Levels

    Time frame: Up to Week 24

  18. Quality of life assessed by FACT-An

    FACT-An: Functional Assessment of Cancer Therapy-Anemia

    Time frame: Up to Week 24

  19. Number of hospitalizations

    Time frame: Up to Week 24

  20. Duration of hospitalizations

    Time frame: Up to Week 24

  21. Plasma concentration of unchanged ASP1517

    Time frame: Up to Week 24

  22. Safety assessed by incidence of adverse events

    Time frame: Up to Week 24

  23. Number of participants with abnormal Laboratory values and/or adverse events related to treatment

    Time frame: Up to Week 24

  24. Number of participants with abnormal Vital signs and/or adverse events related to treatment

    Time frame: Up to Week 24

  25. Number of participants with abnormal 12-lead electrocardiogram (ECG) values

    Any clinically significant adverse changes on the ECG will be reported as adverse events.

    Time frame: Up to Week 24

  26. Safety assessed by ophthalmological examination: fundoscopy

    Time frame: Up to Week 24

  27. Safety assessed by ophthalmological examination: Optical coherence tomography

    Time frame: Up to Week 24

  28. Safety assessed by ophthalmological examination: visual acuity

    Time frame: Up to Week 24

07

Study locations

57 sites
  • Site JP00008
    Aichi, Japan
  • Site JP00018
    Aichi, Japan
  • Site JP00020
    Aichi, Japan
  • Site JP00032
    Aichi, Japan
  • Site JP00033
    Aichi, Japan
  • Site JP00040
    Aichi, Japan
  • Site JP00004
    Ehime, Japan
  • Site JP00055
    Ehime, Japan
  • Site JP00009
    Fukui, Japan
  • Site JP00059
    Fukui, Japan
  • Site JP00014
    Fukuoka, Japan
  • Site JP00049
    Fukuoka, Japan
  • Site JP00010
    Fukushima, Japan
  • Site JP00056
    Fukushima, Japan
  • Site JP00057
    Fukushima, Japan
  • Site JP00030
    Gifu, Japan
  • Site JP00050
    Gifu, Japan
  • Site JP00011
    Gunma, Japan
  • Site JP00026
    Gunma, Japan
  • Site JP00037
    Gunma, Japan
  • Site JP00003
    Hokkaido, Japan
  • Site JP00031
    Hokkaido, Japan
  • Site JP00038
    Hokkaido, Japan
  • Site JP00048
    Hokkaido, Japan
  • Site JP00017
    Ibaraki, Japan
  • Site JP00041
    Ibaraki, Japan
  • Site JP00042
    Ibaraki, Japan
  • Site JP00045
    Ibaraki, Japan
  • Site JP00046
    Ibaraki, Japan
  • Site JP00047
    Ibaraki, Japan
  • Site JP00054
    Ibaraki, Japan
  • Site JP00058
    Ibaraki, Japan
  • Site JP00043
    Kagoshima, Japan
  • Site JP00005
    Kanagawa, Japan
  • Site JP00028
    Kumamoto, Japan
  • Site JP00029
    Kumamoto, Japan
  • Site JP00006
    Kyoto, Japan
  • Site JP00002
    Nagano, Japan
  • Site JP00012
    Nagano, Japan
  • Site JP00027
    Nagano, Japan
  • Site JP00051
    Nagano, Japan
  • Site JP00013
    Nagasaki, Japan
  • Site JP00001
    Niigata, Japan
  • Site JP00034
    Niigata, Japan
  • Site JP00036
    Okayama, Japan
  • Site JP00007
    Osaka, Japan
  • Site JP00015
    Osaka, Japan
  • Site JP00016
    Saitama, Japan
  • Site JP00035
    Saitama, Japan
  • Site JP00044
    Tokushima, Japan
  • Site JP00052
    Tokyo, Japan
  • Site JP00053
    Tokyo, Japan
  • Site JP00021
    Toyama, Japan
  • Site JP00022
    Toyama, Japan
  • Site JP00039
    Toyama, Japan
  • Site JP00024
    Yamagata, Japan
  • Site JP00025
    Yamaguchi, Japan
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. J Am Soc Nephrol. 2020 Jul;31(7):1628-1639. doi: 10.1681/ASN.2019060623. Epub 2020 Jun 3. PubMed 32493693 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2018, 15 months.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 15 months is below that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2016
First posted
Nov 2, 2016
StartActual
Nov 30, 2016
Primary completionActual
Mar 13, 2018
CompletionActual
Mar 15, 2018
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02952092
Collaborators
FibroGen
Responsible party
Sponsor
First posted
Nov 2, 2016
Start date
Nov 30, 2016
Primary completion
Mar 13, 2018
Completion
Mar 15, 2018
Last update
Oct 30, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Roxadustat · Darbepoetin alfa

Start the discussion